Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 29 of the Danish Securities Trading Act, ALK has received notification from Jupiter Asset Management Ltd., that Jupiter Asset Management Ltd. in its capacity as investment manager for a number of clients now holds more than 5% of the share capital of ALK-Abelló A/S.
Jupiter Asset Management Ltd. now owns 5% of the company share capital equivalent to 506,562 B shares.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,200 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, South-East Asia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.
http://www.globenewswire.com/NewsRoom/AttachmentNg/ea4b2d62-c0a9-4e9e-bf69-65831455aa92
